瑞舒伐他汀对脑梗死合并颈动脉粥样硬化患者神经功能缺损及血清hs―CRPIL―6影响.docVIP

瑞舒伐他汀对脑梗死合并颈动脉粥样硬化患者神经功能缺损及血清hs―CRPIL―6影响 　　[摘要] 目的 探讨瑞舒伐他汀治疗脑梗死合并颈动脉粥样硬化患者的神经功能缺损及血清hs-CRP、IL-6的变化。方法 整群选取该院2012年1月―2015年1月收治的符合纳入标准的患者176例作为研究对象，随机分为A组和B组各88例，B组采用常规治疗，A组患者在常规治疗基础上服用瑞舒伐他汀（10 mg/d），两组疗程均为6个月。统计分析两组患者治疗前后的美国国立卫生研究院卒中量表（NIHSS）、改良RANKIN量表（mRS）评分及血清hs-CRP、IL-6的变化。结果 治疗后两组患者血清hs-CRP、IL-6水平均降低，A组患者血清hs-CRP、IL-6水平均显著低于B组[（2.04±0.89）mg/L vs （2.85±0.86）mg/L]、[（45.32±11.48）pg/mL vs（51.65±11.61）pg/mL]（P0.05），而A组的NIHSS评分小于B组[（2.36±0.48） vs （3.93±0.62]（P0.05）。结论 瑞舒伐他汀可通过减少炎症因子的释放、改善内皮功能而减少炎症反应，在减缓动脉粥样硬化进程的同时有效减少了脑梗死对神经功能的损害。 　　[关键词] 瑞舒伐他汀；脑梗死；神经功能；hs-CRP；IL-6 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2016）08（b）-0125-04 　　[Abstract] Objective To study the changes of neurological function and serum hs-CRP and IL-6 in patients with cerebral infarction complicated by carotid atherosclerosis treated with rosuvastatin. Methods Group selection from January 2012 to January 2015， 176 patients were randomly assigned to group A and group B，an average of 88 patients in each group. Patients in both groups were treated with conventional treatment for six months， while rosuvastatin was prescribed to Group A during the whole treament. The U.S. National Institutes of Health Stroke Scale （NIHSS）， modified RANKIN scale （mRS） score， serum hs-CRP and IL-6 were analyzed between the two groups before and after the treatment. Results After the treatment， the serum levels of IL-6 and hs-CRP in the two groups were decreased， the changes in Group A was significantly lower than that in group B[（2.04±0.89） mg/L vs （2.85±0.86） mg/L]、[（45.32±11.48） pg/mL vs （51.65±11.61） pg/mL] （P 0.05）. Compared with group B ， the NIHSS score in group A was lower[（2.36±0.48） vs （3.93±0.62）] （P 0.05）. Conclusion Rosuvastatin can reduce inflammatory reaction by reducing the release of inflammatory factors and improve endothelial function. Meanwhile， rosuvastatin can effectively reduce the damage of cerebral infarction on neurological function impairment by slowing the progression of atherosclerosis. 　　[Ke